Clinical Trial Update: A Clinical Trial of P134 Cells in Recurrent Glioblastoma [Phase 1, Phase 2]

View source ↗

Summary

Tasly's P134 Cells are being studied for recurrent glioblastoma with IDH-wildtype in a Phase 1/2 trial, currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma Idh-wildtype

Drugs mentioned

• P134 Cells (P134 cells)

Snippet

Sponsor: Tasly Pharmaceutical Group Co., Ltd | Conditions: Recurrent Glioblastoma IDH Wildtype | Phase 1, Phase 2 | Status: RECRUITING